Presepsin在脓毒症早期诊断中的价值:发热门诊疑似脓毒症人群的前瞻性研究
该前瞻性观察研究纳入2022年4月至12月北京朝阳医院发热门诊就诊的149例疑似脓毒症患者,按SOFA评分分为低SOFA评分组(SOFA评分≤3,92例)和高SOFA评分组(SOFA评分>3,57例)。入院时采集静脉血检测Presepsin、PCT、CRP、WBC、NEUT,有畏寒或寒战者留取血培养。高SOFA评分组血浆PCT和Presepsin水平显著高于低SOFA评分组(均P<0.01),而WBC、NEUT、CRP及血培养阳性率两组间无显著差异(均P>0.05)。多因素Logistic回归显示Presepsin是发热门诊疑似脓毒症患者脓毒症的早期危险因素(OR=16.96,95%CI 6.35-45.29,P=0.000)。ROC曲线分析显示Presepsin早期诊断脓毒症的AUC为0.832(95%CI 0.771-0.899),显著优于WBC、NEUT、CRP、PCT和血培养。Presepsin最佳cut-off值为646.50 ng/L时,其敏感性和阳性预测值均高于WBC、NEUT、CRP和PCT。结论认为血浆PCT和Presepsin对发热门诊疑似脓毒症患者有早期诊断价值,Presepsin较PCT更敏感,可作为脓毒症早期标志物。
要点
- 发热门诊疑似脓毒症患者中,Presepsin早期诊断脓毒症的AUC为0.832(95%CI 0.771-0.899),优于PCT的0.664(95%CI 0.574-0.753)。
- Presepsin最佳cut-off值为646.50 ng/L时,敏感性89.5%,阳性预测值64.6%,均高于WBC、NEUT、CRP和PCT。
- 高SOFA评分组(SOFA评分>3)血浆Presepsin水平为1129.00(785.50,1766.50)ng/L,显著高于低SOFA评分组(SOFA评分≤3)的563.00(460.50,772.25)ng/L(P<0.01)。
- 高SOFA评分组血浆PCT水平为0.77(0.18,2.02)μg/L,显著高于低SOFA评分组的0.22(0.09,0.71)μg/L(P<0.01)。
- 多因素Logistic回归显示Presepsin是发热门诊疑似脓毒症患者脓毒症的早期危险因素(OR=16.96,95%CI 6.35-45.29,P=0.000)。
适用人群与场景
- 2022年4月至12月北京朝阳医院发热门诊就诊的疑似脓毒症患者。
- 按SOFA评分分为低SOFA评分组(SOFA评分≤3)和高SOFA评分组(SOFA评分>3)。
诊断标准与关键阈值
- 采用序贯器官衰竭评估(SOFA)评分分组:低SOFA评分组SOFA评分≤3,高SOFA评分组SOFA评分>3。
- Presepsin早期诊断脓毒症的最佳cut-off值为646.50 ng/L。
处置流程与药物剂量
- 入院时采集静脉血,采用化学发光酶联免疫分析法检测血浆Presepsin水平。
- 采用酶联免疫荧光法检测血浆PCT水平。
- 采用散射浊度法检测CRP水平。
- 采用自动血细胞分析仪检测WBC和NEUT。
- 有畏寒或寒战的患者入院时采集上肢静脉血进行血培养。
研究设计与关键结果
- 前瞻性观察研究纳入149例发热门诊疑似脓毒症患者,其中低SOFA评分组92例,高SOFA评分组57例。
- 高SOFA评分组血浆PCT水平为0.77(0.18,2.02)μg/L,显著高于低SOFA评分组的0.22(0.09,0.71)μg/L(P<0.01)。
- 高SOFA评分组血浆Presepsin水平为1129.00(785.50,1766.50)ng/L,显著高于低SOFA评分组的563.00(460.50,772.25)ng/L(P<0.01)。
- 高SOFA评分组与低SOFA评分组WBC、NEUT、CRP及血培养阳性率均无显著差异:WBC(×10^9/L)11.32±5.47 vs. 11.14±5.29,NEUT(×10^9/L)9.88±4.89 vs. 9.60±5.10,CRP(mg/L)54.05(15.95,128.90) vs. 46.11(19.60,104.60),血培养阳性率42.3%(11/26) vs. 29.4%(10/34),均P>0.05。
- 多因素Logistic回归分析显示Presepsin是发热门诊疑似脓毒症患者脓毒症的早期危险因素(OR=16.96,95%CI 6.35-45.29,P=0.000)。
- ROC曲线分析显示Presepsin早期诊断脓毒症的AUC为0.832(95%CI 0.771-0.899),显著优于WBC的0.522(95%CI 0.424-0.619)、NEUT的0.532(95%CI 0.435-0.629)、CRP的0.533(95%CI 0.435-0.632)、PCT的0.664(95%CI 0.574-0.753)和血培养的0.554(95%CI 0.458-0.650)。
- Presepsin最佳cut-off值为646.50 ng/L时,其敏感性和阳性预测值均高于WBC、NEUT、CRP和PCT:敏感性89.5% vs. 38.6%、68.4%、38.6%、57.9%;阳性预测值64.6% vs. 44.9%、44.3%、47.8%、55.9%。
证据类型、等级与局限
- 证据类型:前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在发热门诊疑似脓毒症患者中,Presepsin可作为早期诊断脓毒症的标志物,其敏感性高于PCT。
- Presepsin最佳cut-off值为646.50 ng/L,可作为早期识别脓毒症的参考阈值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To analyze the early diagnostic value of plasma soluble cluster of differentiation 14 subtype (sCD14-ST, Presepsin) in sepsis in a population with suspected sepsis in fever clinic.
METHODS: A prospective observational study was conducted. The patients admitted to the fever clinic of Beijing Chaoyang Hospital from April to December 2022 were enrolled as the study objects. According to sequential organ failure assessment (SOFA) score, the patients were divided into low SOFA score group (SOFA score ≤3) and high SOFA score group (SOFA score > 3). Venous blood was collected at the time of admission. The level of plasma Presepsin was detected by chemiluminescence enzyme-linked immunoassay. The level of plasma procalcitonin (PCT) was detected by enzyme-linked immunofluorescence method. The level of C-reactive protein (CRP) was detected by scattering turbidimetry. White blood cell count (WBC) and neutrophil count (NEUT) were measured by automatic blood cell analyzer. For patients with fear of cold or chills, venous blood of upper limbs was taken for blood culture at the time of admission. The differences in inflammatory biomarkers were compared between the two groups. Binary multivariate Logistic regression analysis was used to screen the early risk factors of sepsis in fever outpatients with suspected sepsis. Receiver operator characteristic curve (ROC curve) was drawn to investigate the early diagnostic value of Presepsin and other inflammatory markers in sepsis, and to analyze the optimal cut-off value.
RESULTS: A total of 149 fever outpatients with suspected sepsis were enrolled, including 92 patients with low SOFA score and 57 patients with high SOFA score. Plasma PCT and Presepsin levels in the high SOFA score group were significantly higher than those in the low SOFA score group [PCT (μg/L): 0.77 (0.18, 2.02) vs. 0.22 (0.09, 0.71), Presepsin (ng/L): 1 129.00 (785.50, 1 766.50) vs. 563.00 (460.50, 772.25), both P < 0.01]. There was no significant difference in WBC, NEUT, CRP or positive rate of blood culture between the high and low SOFA score groups [WBC (×109/L): 11.32±5.47 vs. 11.14±5.29, NEUT (×109/L): 9.88±4.89 vs. 9.60±5.10, CRP (mg/L): 54.05 (15.95, 128.90) vs. 46.11 (19.60, 104.60), blood culture positivity rate: 42.3% (11/26) vs. 29.4% (10/34), all P > 0.05]. Multivariate Logistic regression analysis showed that Presepsin was an early risk factor for sepsis in suspected sepsis patients in fever clinics [odds ratio (OR) = 16.96, 95% confidence interval (95%CI) was 6.35-45.29, P = 0.000]. ROC curve analysis showed that the early diagnostic value of Presepsin in sepsis was significantly better than WBC, NEUT, CRP, PCT, and blood culture [the area under the ROC curve (AUC) and 95%CI: 0.832 (0.771-0.899) vs. 0.522 (0.424-0.619), 0.532 (0.435-0.629), 0.533 (0.435-0.632), 0.664 (0.574-0.753), 0.554 (0.458-0.650)]. When the optimal cut-off value of Presepsin was 646.50 ng/L, its sensitivity and positive predictive value were higher than those of WBC, NEUT, CRP, and PCT (sensitivity: 89.5% vs. 38.6%, 68.4%, 38.6%, 57.9%; positive predictive value: 64.6% vs. 44.9%, 44.3%, 47.8%, 55.9%).
CONCLUSIONS: Plasma PCT and Presepsin have early diagnostic value for sepsis in suspected sepsis patients in fever clinics, and Presepsin is more sensitive than PCT and can be used as an early marker of sepsis.
参考来源
- Zong X, Liu Y, Gu L, et al. [Early diagnostic value of Presepsin in sepsis: a prospective study on a population with suspected sepsis in fever clinics]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 38813625. doi:10.3760/cma.j.cn121430-20230828-00700
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。